The Morning Brief cover image

Biocon's Biosimilar Blues

The Morning Brief

00:00

Bicon Biosmillers - A Look at the Prospects

It will be unique in the industry terms of the products that we've already commercialized in the market. From a financial standpoint, the estimates that we've got for the beatrices biosmillers business for calendar year 23, we believe will be generating a revenue of over one point one billion dollars and a strong bit of to 250 million dollars. It then provides us the kind of empatis we want to become world eating player. I also got shahas to take us through bicon's outlook and to outline the significance of this deal.

Play episode from 13:56
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app